People · Operator
Named in public records as an officer, director or promoter · active 2015–2024 · Biotechnology, Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Novus Therapeutics, Inc. | — | Biotechnology | Series D+ | $226.8M | $575.7M | 2020 |
| Transposon Therapeutics, Inc. | — | Pharmaceuticals | Series C | $59.1M | $40.6M | 2022 |
| Carbylan Therapeutics, Inc. | — | Other Health Care | Series A | $15.0M | $80.7M | 2015 |
Keith A. Katkin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Keith A. Katkin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Albert Cha | 1 | 9 |
| Campbell Murray | 1 | 9 |
| Timothy J. Barberich | 1 | 7 |
| John McBride | 1 | 7 |
| Erez Chimovits | 1 | 7 |
| Brent Ahrens | 1 | 7 |
| Bryan Smith | 1 | 6 |
| Dennis Podlesak | 1 | 6 |
| James Robinson | 1 | 6 |
| Chris Ehrlich | 1 | 6 |
| Guy Nohra | 1 | 5 |
| Eckard Weber, M.D. | 1 | 5 |
| Lynne Rollins | 1 | 5 |
| Campbell A. Murray | 1 | 4 |
| Mark Weeks | 1 | 4 |
| Seth L. Harrison | 1 | 4 |
| David Kessler | 1 | 3 |
| Cheryl Cohen | 1 | 3 |
| Guy P. Nohra | 1 | 3 |
| Reinhard J. Ambros | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.